• Institute of Good Manufacturing Practices India
  • Global accredited training & certification provider
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India
  • Approved Training Institute of Food Safety and Standards Authority of India (FSSAI)
  • Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017

Trusted by organizations & training participants in over 30 countries
Training | Certification | Education | Research


First sANDA (Supplemental Abbreviated New Drug Application) approved by USFDA for Glenmark Pharmaceuticals Manufacturing Facility In Monroe, North Carolina

Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with presence in more than 50 countries and has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease and dermatology.

The Monroe, North Carolina facility is Glenmark's first manufacturing site in the U.S., wherein Glenmark has invested more than $100 million into the facility and is designed to manufacture a variety of fixed dose pharmaceutical formulations such as 300-400 million tablets and capsules, 20-25 million vials and pre-filled syringes and 25-30 million ampoules for inhaled formulations. The U.S. Food & Drug Administration provided its first supplemental Abbreviated New Drug Application (sANDA) approval to this facility for Atovaquone and Proguanil Hydrochloride Tablets, 250 MG/100 MG and 62.5 MG/25 MG, a generic version of GlaxoSmithKline's Malarone® (atovaquone and proguanil hydrochloride) Tablets.

According to Robert Matsuk, President, North America & Global API at Glenmark Pharmaceuticals, “the approval is significant from the point of view that Monroe, N.C. site will expand company’s portfolio by providing the manufacturing foundation for future product approvals and also the investment made in the site will continue to create new, high-quality jobs in the Monroe community, where the company has a commitment to long-term growth and expansion."